Loading
Life sciences · Journal article
Frontiers in Immunology · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Chimeric Antigen Receptor T (CAR-T) cell therapy has emerged as a promising therapeutic option, particularly for refractory and relapsed leukemias. However, its efficacy in treating solid tumors, including lung, ovarian, gastric, and breast cancers, remains limited by several challenges. Recent studies have highlighted CAR-T cell immunotherapy as a potential treatment for these malignancies, utilizing genetically engineered T cells that target specific tumor antigens. For successful therapy, it is crucial to identify antigens that are selectively expressed on tumor cells but not on normal tissues. In lung cancer, however, the lack of specific tumor-associated antigens, the immunosuppressive tumor microenvironment, limited CAR-T cell infiltration, and off-target effects complicate the development of effective CAR-T therapies. This review outlines the fundamental structure and generation of CAR-T cells, summarizes key tumor-associated antigens targeted in clinical trials for these cancers, and discusses the current challenges and emerging strategies. The goal is to provide insights and potential approaches to enhance the design and execution of preclinical and clinical CAR-T cell therapies for these solid tumors.